Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
|
Parniak MA
|
2013
|
Retrovirology
|
The hepatitis B virus ribonuclease h is sensitive to inhibitors of the human immunodeficiency virus ribonuclease h and integrase enzymes.
|
Parniak MA
|
2013
|
PLoS pathogens
|
Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.
|
Parniak MA
|
2013
|
Journal of medicinal chemistry
|
Effects of 4' - and 2-Substitutions on the Bioactivity of 4' -Ethynyl-2-Fluoro-2' -Deoxyadenosine.
|
Parniak MA
|
2013
|
Antimicrobial agents and chemotherapy
|
Biochemical Mechanism of HIV-1 Resistance to Rilpivirine.
|
Parniak MA
|
2012
|
The Journal of biological chemistry
|
Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain.
|
Parniak MA
|
2012
|
Chemical biology & drug design
|
Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase.
|
Parniak MA
|
2012
|
Antimicrobial agents and chemotherapy
|
Effect of translocation defective reverse transcriptase inhibitors on the activity of n348i, a connection subdomain drug resistant hiv-1 reverse transcriptase mutant.
|
Parniak MA
|
2012
|
Cellular and molecular biology (Noisy-le-Grand, France)
|
Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity.
|
Parniak MA
|
2012
|
Biology
|
Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor.
|
Parniak MA
|
2011
|
Chemical biology & drug design
|
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
|
Parniak MA
|
2011
|
Nucleic acids research
|
The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.
|
Parniak MA
|
2011
|
Cellular and molecular biology (Noisy-le-Grand, France)
|
Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies.
|
Parniak MA
|
2011
|
Journal of chemical information and modeling
|
The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site.
|
Parniak MA
|
2010
|
Retrovirology
|
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.
|
Parniak MA
|
2009
|
Journal of molecular biology
|
Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
|
Parniak MA
|
2008
|
Bioorganic & medicinal chemistry
|
Inhibitors of HIV-1 reverse transcriptase.
|
Parniak MA
|
2008
|
Advances in pharmacology (San Diego, Calif.)
|
Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptase.
|
Parniak MA
|
2008
|
PloS one
|
Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection.
|
Parniak MA
|
2007
|
Journal of molecular biology
|
Synthesis of AZTpSpCX2ppSA and AZTpSpCX2ppSAZT: hydrolysis-resistant potential inhibitors of the AZT excision reaction of HIV-1 RT.
|
Parniak MA
|
2007
|
Organic letters
|
3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase.
|
Parniak MA
|
2007
|
Biochemistry
|
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.
|
Parniak MA
|
2006
|
ACS Chem Biol
|
Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.
|
Parniak MA
|
2005
|
Journal of virology
|
Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones.
|
Parniak MA
|
2005
|
Nucleic acids research
|
Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
|
Parniak MA
|
2005
|
Biochemistry
|
The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1.
|
Parniak MA
|
2005
|
The Journal of biological chemistry
|
A capillary electrophoretic assay for ribonuclease H activity.
|
Parniak MA
|
2004
|
Analytical biochemistry
|
Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.
|
Parniak MA
|
2004
|
The international journal of biochemistry & cell biology
|
A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity.
|
Parniak MA
|
2003
|
Analytical biochemistry
|
Structure-activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysis.
|
Parniak MA
|
2003
|
Protein science : a publication of the Protein Society
|
Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase: comparison between initiation and elongation of reverse transcription and between (-) and (+) strand DNA synthesis.
|
Parniak MA
|
2002
|
The Journal of biological chemistry
|
Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones.
|
Parniak MA
|
2002
|
The Journal of biological chemistry
|
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.
|
Parniak MA
|
2002
|
Antiviral research
|
Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana.
|
Parniak MA
|
2002
|
Antiviral therapy
|
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
|
Parniak MA
|
2002
|
Antimicrobial agents and chemotherapy
|
Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors.
|
Parniak MA
|
2002
|
Molecular pharmacology
|
A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.
|
Parniak MA
|
2002
|
Antimicrobial agents and chemotherapy
|
Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
|
Parniak MA
|
2000
|
Cellular and molecular life sciences : CMLS
|
Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1.
|
Parniak MA
|
2000
|
Journal of molecular biology
|
Mutational analysis of Lys65 of HIV-1 reverse transcriptase.
|
Parniak MA
|
2000
|
Biochem J
|
Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
|
Parniak MA
|
2000
|
The Journal of biological chemistry
|
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
|
Parniak MA
|
2000
|
J Virol
|
Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
|
Parniak MA
|
2000
|
Biochemistry
|
Inhibitors of HIV-1 reverse transcriptase.
|
Parniak MA
|
2000
|
Advances in pharmacology (San Diego, Calif.)
|
Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
|
Parniak MA
|
1999
|
Antiviral therapy
|
HIV resistance to zidovudine: the role of pyrophosphorolysis.
|
Parniak MA
|
1999
|
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
|
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
|
Parniak MA
|
1999
|
Antimicrobial agents and chemotherapy
|
A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.
|
Parniak MA
|
1998
|
The Journal of general virology
|
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.
|
Parniak MA
|
1998
|
Biochemistry
|
Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
|
Parniak MA
|
1998
|
Journal of molecular biology
|
Physicochemical and biochemical properties of 2',5'-linked RNA and 2',5'-RNA:3',5'-RNA "hybrid" duplexes.
|
Parniak MA
|
1998
|
Biochemistry
|
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1.
|
Parniak MA
|
1997
|
Journal of molecular biology
|
Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.
|
Parniak MA
|
1997
|
Biochemistry
|
Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
|
Parniak MA
|
1997
|
J Virol
|
Inhibitory potency of R-region specific antisense oligonucleotides against in vitro DNA polymerization and template-switching reactions catalysed by HIV-1 reverse transcriptase.
|
Parniak MA
|
1997
|
Int J Biochem Cell Biol
|
The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
|
Parniak MA
|
1997
|
Biochemistry
|
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.
|
Parniak MA
|
1997
|
Journal of virology
|
Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.
|
Parniak MA
|
1996
|
Journal of virology
|
Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.
|
Parniak MA
|
1996
|
Journal of virology
|
HIV-1 reverse transcriptase shows no specificity for the binding of primer tRNA(Lys3).
|
Parniak MA
|
1996
|
Biochemical and biophysical research communications
|
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
|
Parniak MA
|
1996
|
AIDS (London, England)
|
Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase.
|
Parniak MA
|
1996
|
Protein expression and purification
|
Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
|
Parniak MA
|
1996
|
Molecular pharmacology
|
The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase.
|
Parniak MA
|
1996
|
The Journal of biological chemistry
|
Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.
|
Parniak MA
|
1995
|
Biochemistry
|
[Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds].
|
Parniak MA
|
1995
|
Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie
|
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.
|
Parniak MA
|
1995
|
Proceedings of the National Academy of Sciences of the United States of America
|
Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.
|
Parniak MA
|
1995
|
Biochemistry
|
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.
|
Parniak MA
|
1994
|
The Journal of biological chemistry
|
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
|
Parniak MA
|
1994
|
Antimicrobial agents and chemotherapy
|
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
|
Parniak MA
|
1994
|
The Journal of biological chemistry
|
Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.
|
Parniak MA
|
1994
|
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
|
Generation and characterization of murine monoclonal antibodies reactive against N-terminal and other regions of HIV-1 reverse transcriptase.
|
Parniak MA
|
1993
|
Journal of medical virology
|
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
|
Parniak MA
|
1993
|
Antimicrob Agents Chemother
|
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
|
Parniak MA
|
1992
|
Journal of virology
|
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
|
Parniak MA
|
1992
|
J Virol
|
Variable tRNA content in HIV-1IIIB.
|
Parniak MA
|
1992
|
Biochemical and biophysical research communications
|
Clinical significance and characterization of AZT-resistant strains of HIV-1.
|
Parniak MA
|
1991
|
The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
|
Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
|
Parniak MA
|
1990
|
Annals of the New York Academy of Sciences
|